**Poster Session 20**

**BLEXIT - best perioperative outcomes from cystectomy**

**Saturday, 25 March**
**16:00 - 17:30**

**Location:** Room Copenhagen, North Hall (Level 1)

**Chairs:** P. Anderson, Melbourne (AU)
P. Gontero, Turin (IT)

**Aims and objectives of this session**
To understand how to optimize perioperative outcomes in cystectomy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

### 261

**Postoperative psoas muscle loss and nutritional deterioration after radical cystectomy for patients with invasive bladder cancer**

*By:* Miyake M.¹, Morizawa Y.¹, Hori S.¹, Marugami N.², Shimada K.³, Gotoh D.³, Tatsumi Y.¹, Nakai Y.¹, Anai S.¹, Tanaka N.¹, Fujimoto K.¹

*Institutes:* Nara Medical University, Dept. of Urology, Nara, Japan, ²Nara Medical University, Dept. of Radiology, Nara, Japan, ³Nara City Hospital, Dept. of Pathology, Nara, Japan

### 262

**Robot-assisted laparoscopic cystectomy vs. open mini-laparotomy cystectomy: Evaluation of anti-inflammatory potential of CO2-pneumoperitoneum in a randomized porcine study**

*By:* Kingo P.S.¹, Rasmussen T.M.¹, Jakobsen L.K.¹, Palmfeldt J.², Borre M.¹, Nørregaard R.², Jensen J.B.¹

*Institutes:* ¹Aarhus University Hospital, Skejby, Dept. of Urology, Aarhus N, Denmark, ²Aarhus University Hospital, Skejby, Dept. of Clinical Medicine, Aarhus N, Denmark

### 263

Withdrawn

*By:*

*Institutes:*

### 264

**20-gene expression signature to predict lymph node positive disease at radical cystectomy for muscle-invasive bladder cancer: Not validated**

*By:* Van Kessel K.¹, Van De Werken H.², Lurkin I.¹, Ziel–Van Der Made A.¹, Zwarthoff E.¹, Boormans J.³

*Institutes:* ¹Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ²Erasmus MC, Cancer Computational Biology Center (CCBC), Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

### 265

**The use of antibiotic prophylaxis in patients undergoing radical cystectomy for bladder cancer**

*By:* Haider M.¹, Mayr R.¹, Fritsche H.-M.¹, Ladurner C.², Pycha A.², Comploj E.², Lemire F.³, Lacombe L.³, Fradet Y.³, Lodde M.³

*Institutes:* ¹University of Regensburg, Dept. of Urology, Regensburg, Germany, ²General Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, ³Laval University, Dept. of Urology, Québec, Canada

### 266

**Can radical cystectomy be performed safely in the metastatic setting? Location of metastatic bladder cancer as a determinant of in-hospital mortality**

*By:* Zaffuto E.¹, Moschini M.¹, Leyh-Bannurah S.-R.², Gazdovich S.³, Dell'Oglio P.¹, Pompe R.², Shariat S.⁴, Montorsi F.¹, Briganti A.¹, Saad F.⁵, Karakiewicz P.³

*Institutes:* ¹IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, ²Prostate Cancer Center Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany, ³University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵University of Montreal Health
267

**Increasing use of incontinent urinary diversion: A total population analysis of radical cystectomies in Germany from 2006 to 2013**

By: Groeben C., Koch R., Baunacke M., Wirth M., Huber J.

Institutes: TU Dresden, Medical Faculty Carl Gustav Carus, Dept. of Urology, Dresden, Germany, TU Dresden, Medical Faculty Carl Gustav Carus, Dept. of Medical Statistics and Biometry, Dresden, Germany

268

**Incidence and risk factors for venous thromboembolism after transurethral resection of bladder tumor: A population-based analysis**


Institutes: IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, Prostate Cancer Center Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany, University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, Medical University of Vienna, Dept. of Urology, Vienna, Austria, University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada

269

**Diarrhea as a limiting factor of quality of life after radical cystectomy: Results from a cross-sectional study evaluating long-term bowel issues in bladder cancer patients**

By: Hupe M.C., Vahlensieck W., Hennig M., Ozimek T., Struck J., Tezval H., Merseburger A., Kuczyk M., Kramer M.

Institutes: University Hospital Schleswig-Holstein, Campus Luebeck, Dept. of Urology, Luebeck, Germany, Kurpark-Klinik, Dept. of Urology, Bad Nauheim, Germany, Hanover Medical School, Dept. of Urology, Hanover, Germany

270

**Low psoas muscle volume indicates long hospitalization after radical cystectomy**

By: Kawahara T., Saitoh Y., Miyoshi Y., Uemura H.

Institutes: Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan

271

**Efficacy of long acting sandostatin on reducing mucus production in patients with ileal neobladder**

By: Khorrami M.H.

Institutes: Isfahan University of Medical Sciences, Dept. of Urology, Isfahan, Iran

272

**The BAUS radical cystectomy audit 2014/2015 - an update on current practice and an analysis of the effect of centre and surgeon case volume**

By: Khadhouri S., Miller C., Cresswell J., Rowe E., Fowler S., Hounsome L., McGrath J.S.

Institutes: Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, South Tees NHS Trust, Dept. of Urology, Middlesbrough, United Kingdom, North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, BAUS, Dept. of Surgery, London, United Kingdom, Public Health England, Dept. of Public Health, London, United Kingdom

273

**Pure histological variants are associated with poor survival at radical cystectomy in patients with bladder cancer**


Institutes: IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, Medical University of Vienna, Dept. of Urology, Vienna, Austria

274

**Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder**


Institutes: Brigham and Women’s Hospital, Harvard Medical School, Division of Urological Surgery
and Center For Surgery and Public Health, Boston, United States of America, 2Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For, Boston, United States of America, 3Henry Ford Health System, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 4Pitié-Salpêtrière, APHP, University Paris VI, Dept. of Urology, Paris, France, 5Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 6Brigham and Women's Hospital, Harvard Medical School, Dept. of Radiation Oncology, Boston, United States of America

17:19 - 17:26

Summary

P. Anderson, Melbourne (AU)